|
US2007184459A1
|
|
Methods of inhibiting cancer growth by binding to nuclear receptors
|
|
US2009133136A1
|
|
Inducible SIRNA expression cassette and method of use
|
|
AU2006206555A1
|
|
Novel quinolinium salts and derivatives
|
|
CN101106992A
|
|
Novel quinolinium salts and derivatives
|
|
WO2006020557A2
|
|
Methods of using or identifying agents that inhibit cancer growth
|
|
WO2006019429A2
|
|
Methods of identifying and using agents that increase inhibition of or resistance to hcv infection
|
|
US2006234249A1
|
|
Novel assays for assessing cancerous cell growth
|
|
WO2005098440A2
|
|
Methods for identifying agents useful for the treatment of neurodegenerative diseases
|
|
EP1677739A2
|
|
Methods of identifying agents that inhibit the growth of cancer cells
|
|
WO2005017112A2
|
|
Methods of inhibiting cancer growth by binding to nuclear receptors
|
|
US2004259079A1
|
|
Substantially complete ribozyme libraries
|
|
CA2515688A1
|
|
Sirna libraries optimized for predetermined protein families
|
|
WO2004009796A2
|
|
Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
|
|
EP1534840A2
|
|
Novel sirna gene libraries and methods for their production and use
|
|
US2004071708A1
|
|
GPR 39 modulators that control cancerous cell growth
|
|
AU2002314780A1
|
|
Agents that regulate apoptosis
|
|
WO0170982A2
|
|
Brca-1 regulators and methods of use
|
|
EP1676915A2
|
|
Ribozyme therapy for the treatment of proliferative skin diseases
|
|
AU1345601A
|
|
Ribozyme therapy for the treatment of proliferative skin and eye diseases
|
|
US6770633B1
|
|
Ribozyme therapy for the treatment of proliferative skin and eye diseases
|
